Sec Form 13G Filing - UBS Oncology Impact Fund L.P. @ MEI Pharma Inc.

Sec Form 13G Filing - UBS Oncology Impact Fund L.P. filing for MEI Pharma Inc. (MEIP) - 2023-02-09

Insider filing report for Changes in Beneficial Ownership

Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)*

MEI Pharma, Inc.

(Name of Issuer)

Common Stock, par value $0.00000002

(Title of Class of Securities)

55279B202

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 10

CUSIP No. 55279B202

Page 2 of 10

CUSIP No. 55279B202

Page 3 of 10

CUSIP No. 55279B202

Page 4 of 10

CUSIP No. 55279B202

Page 5 of 10

Item 1.

(a)

Name of Issuer

MEI Pharma, Inc.

(b)

Address of Issuer’s Principal Executive Offices

11455 El Camino Real

San Diego, CA 92130

Item 2.

(a)

Name of Person Filing

UBS Oncology Impact Fund L.P. (“UBS Oncology”)

Oncology Impact Fund (Cayman) Management LP (“Oncology Cayman”)

BioImpact Capital LLC (“BioImpact”)

Ansbert Gadicke

(b)

The address of the principal place of business for each of the Filing Persons is c/o MPM Capital LLC, 399 Boylston Street, Boston, MA 02116, other than UBS Oncology and Oncology Cayman, whose address is 1st Floor, 2 Hill Street, St Helier, Jersey, JE1 4FS.

(c)

Citizenship

UBS Oncology and Oncology Cayman are organized in the Cayman Islands and BioImpact is organized in Delaware. Mr. Gadicke is a United States citizen.

(d)

Title of Class of Securities

Common Stock, par value $0.00000002 per share (“Common Stock”)

(e)

CUSIP Number

55279B202

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

Page 6 of 10

Item 4.

Ownership


UBS Entity	Shares Held Directly		Sole Voting Power		Shared Voting Power		Sole Dispositive Power		Shared Dispositive Power		Beneficial Ownership		Percentage of Class
UBS Oncology		0		0		0		0		0		0		0.0	%
Oncology Cayman		0		0		0		0		0		0		0.0	%
BioImpact		0		0		0		0		0		0		0.0	%
Ansbert Gadicke		0		0		0		0		0		0		0.0	%

Item 5.

Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☑.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group

Not Applicable

Item 9.

Notice of Dissolution of a Group

Not Applicable

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under

§ 240.14a-11.

Page 7 of 10

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 8, 2023


UBS ONCOLOGY IMPACT FUND, L.P.

By:		Oncology Impact Fund (Cayman) Management L.P.,
		its General Partner
By:		BioImpact Capital LLC,
		Its General Partner

By:		/s/ Ansbert Gadicke
Name:		Ansbert Gadicke
Title:		Managing Partner

ONCOLOGY IMPACT FUND (CAYMAN) MANAGEMENT L.P.

By:		BioImpact Capital LLC,
		Its General Partner

By:		/s/ Ansbert Gadicke
Name:		Ansbert Gadicke
Title:		Managing Partner

BIOIMPACT CAPITAL LLC

By:		/s/ Ansbert Gadicke
Name:		Ansbert Gadicke
Title:		Managing Partner

By:		/s/ Ansbert Gadicke
Name:		Ansbert Gadicke

Page 8 of 10

Exhibits


A		Joint Filing Agreement

Page 9 of 10

Name of Reporting Persons

UBS Oncology Impact Fund L.P.

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Cayman Islands